Search
Displaying 291–300 of 612 for “retinal diseases”
-
Sepul Bio Launches Phase 2b Clinical Trial for USH2A RNA Therapy
Research NewsKnown as ultevursen, the USH2A RNA therapy was licensed from ProQR.
-
AAVantgarde Bio’s Dual-Vector USH1B Gene Therapy Moves into Phase 1/2 Clinical Trial
Research NewsThe trial is the first ever for a dual AAV gene therapy delivered to the retina.
-
Research News
Known as antisense oligonucleotides, the treatments performed encouragingly in ProQR’s clinical trials
-
New Report: Vitamin A Supplementation Provides No Vision Benefit to RP Patients
Research NewsThe report also concludes that vitamin E supplementation accelerates vision loss for RP patients
-
Ocugen Reports Updated Results for Clinical Trial of Modifier Gene Therapy
Research NewsThe company is also launching modifier gene therapy clinical trials for GA and Stargardt disease
-
SparingVision Recruiting for Clinical Trial of Cone-Preserving Gene Therapy for RP
Research NewsFirst cohort of patients has been dosed in Phase ½ clinical trial taking place in Pittsburgh and Paris
-
Atsena Receives FDA Authorization to Launch a Gene Therapy Clinical Trial for XLRS
Research NewsKnown as The Lighthouse Study, the Phase ½ trial is expected to begin in mid-2023
-
Opus Genetics Acquires Rights to Gene Therapies for BEST1 and RP (RHO)
Research NewsThe company plans to seek clinical trial authorization for the BEST1 gene therapy during the second half of 2023
-
Research News
The company is planning a late-stage trial for its achromatopsia (CNGB3) gene therapy.
-
Bionic Sight’s Optogenetic Therapy Enables Blind Patients to Detect Light and Motion in Early Trial
Research NewsThe approach holds potential for restoring vision to people with little or no vision
.png)
.png)
